TargetMol

N-Methyl amisulpride

Product Code:
 
TAR-T33703
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T33703-10mg10mg£338.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T33703-50mg50mg£884.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T33703-100mg100mg£1,457.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
N-Methyl amisulpride is an impurity of Amisulpride.
CAS:
1391054-22-0
Formula:
C18H29N3O4S
Molecular Weight:
383.51
Purity:
0.98
SMILES:
CCN1CCCC1CN(C)C(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC

References

Gan TJ, Kranke P, Minkowitz HS, Bergese SD, Motsch J, Eberhart L, Leiman DG, Melson TI, Chassard D, Kovac AL, Candiotti KA, Fox G, Diemunsch P. Intravenous Amisulpride for the Prevention of Postoperative Nausea and Vomiting: Two Concurrent, Randomized, Double-blind, Placebo-controlled Trials. Anesthesiology. 2017 Feb;126(2):268-275. doi: 10.1097/ALN.0000000000001458. PubMed PMID: 27902493. Arora M, Banal R, Praharaj SK, Mahajan V. Amisulpride Augmentation in Acute Catatonia. Am J Ther. 2017 Jul/Aug;24(4):e381-e385. doi: 10.1097/MJT.0000000000000311. PubMed PMID: 26270797. Barnes TR, Leeson VC, Paton C, Marston L, Davies L, Whittaker W, Osborn D, Kumar R, Keown P, Zafar R, Iqbal K, Singh V, Fridrich P, Fitzgerald Z, Bagalkote H, Haddad PM, Husni M, Amos T. Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness. Health Technol Assess. 2017 Sep;21(49):1-56. doi: 10.3310/hta21490. PubMed PMID: 28869006; PubMed Central PMCID: PMC5601255. Herrstedt J, Summers Y, Daugaard G, Christensen TB, Holmskov K, Taylor PD, Fox GM, Molassiotis A. Amisulpride in the prevention of nausea and vomiting induced by cisplatin-based chemotherapy: a dose-escalation study. Support Care Cancer. 2018 Jan;26(1):139-145. doi: 10.1007/s00520-017-3825-2. Epub 2017 Aug 11. PubMed PMID: 28801850.